NO20032101D0 - Apoliprotein analoger - Google Patents

Apoliprotein analoger

Info

Publication number
NO20032101D0
NO20032101D0 NO20032101A NO20032101A NO20032101D0 NO 20032101 D0 NO20032101 D0 NO 20032101D0 NO 20032101 A NO20032101 A NO 20032101A NO 20032101 A NO20032101 A NO 20032101A NO 20032101 D0 NO20032101 D0 NO 20032101D0
Authority
NO
Norway
Prior art keywords
apoliprotein
analogues
apoliprotein analogues
Prior art date
Application number
NO20032101A
Other languages
English (en)
Other versions
NO331274B1 (no
NO20032101L (no
Inventor
Jonas Graversen
Soeren Moestrup
Original Assignee
Proteopharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteopharma Aps filed Critical Proteopharma Aps
Publication of NO20032101D0 publication Critical patent/NO20032101D0/no
Publication of NO20032101L publication Critical patent/NO20032101L/no
Publication of NO331274B1 publication Critical patent/NO331274B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20032101A 2000-11-10 2003-05-09 Apolipoproteinanaloger NO331274B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200001682 2000-11-10
DKPA200100057 2001-01-15
US26402201P 2001-01-26 2001-01-26
PCT/DK2001/000739 WO2002038609A2 (en) 2000-11-10 2001-11-09 Apolipoprotein conjugates

Publications (3)

Publication Number Publication Date
NO20032101D0 true NO20032101D0 (no) 2003-05-09
NO20032101L NO20032101L (no) 2003-07-08
NO331274B1 NO331274B1 (no) 2011-11-14

Family

ID=27222453

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032101A NO331274B1 (no) 2000-11-10 2003-05-09 Apolipoproteinanaloger

Country Status (10)

Country Link
US (4) US6897039B2 (no)
EP (2) EP1335938B1 (no)
JP (2) JP4344136B2 (no)
CN (1) CN1268641C (no)
AU (2) AU2002213843B2 (no)
BR (1) BR0115257A (no)
CA (1) CA2428114C (no)
CY (1) CY1111118T1 (no)
NO (1) NO331274B1 (no)
WO (1) WO2002038609A2 (no)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
WO2002048333A2 (en) * 2000-12-12 2002-06-20 Lexicon Genetics Incorporated Novel human kinases and uses thereof
EP1353666B1 (en) * 2001-01-02 2013-07-03 The Cleveland Clinic Foundation Myeloperoxidase, a risk indicator for cardiovascular disease
MXPA04002848A (es) * 2001-09-28 2005-06-06 Esperion Therapeutics Inc Prevencion y tratamiento de restenosis por administracion local de medicamento.
WO2004069795A2 (en) * 2003-02-03 2004-08-19 Pfizer Products Inc. Diagnosis and treatment of chronic tissue damage
AU2004212944B2 (en) * 2003-02-14 2008-08-21 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
NZ543122A (en) * 2003-03-24 2008-07-31 Sequoia Pharmaceuticals Inc An HIV fusion inhibitor peptide covalently linked to a blood protein
US20060166891A1 (en) * 2003-04-22 2006-07-27 Sircar Jagadish C Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
NZ561162A (en) 2003-04-23 2009-11-27 Hoffmann La Roche Human granzyme B protease variant wherein cystein 228 is mutated to phenylalanine
US7459286B1 (en) 2003-10-22 2008-12-02 The Cleveland Clinic Foundation Assessing the risk of a major adverse cardiac event in patients with chest pain
ATE546734T1 (de) * 2003-12-05 2012-03-15 Cleveland Clinic Foundation Risikomarker für eine herzkreislaufkrankheit
US20050176623A1 (en) * 2004-02-11 2005-08-11 Neil Wagle Non-invasive treatment of disease using amphipathic compounds
US20100028995A1 (en) * 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
JP2007531537A (ja) * 2004-04-06 2007-11-08 セダーズ−シナイ　メディカル　センター アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
WO2006020498A2 (en) * 2004-08-11 2006-02-23 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
JP2009505652A (ja) * 2005-08-26 2009-02-12 セレニス セラピューティクス ホールディング エスア 乳酸菌においてアポリポタンパク質遺伝子生成物を生成するための組成物および方法
US20070117179A1 (en) * 2005-09-27 2007-05-24 Invitrogen Corporation In vitro protein synthesis systems for membrane proteins that include adolipoproteins and phospholipid-adolipoprotein particles
US20080248565A1 (en) * 2007-03-01 2008-10-09 Invitrogen Corporation Isolated phospholipid-protein particles
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
WO2008133225A1 (ja) * 2007-04-23 2008-11-06 Nihon Pharmaceutical Co., Ltd. 急性肝炎の治療又は劇症肝炎の予防・治療剤
CA2701705A1 (en) * 2007-10-08 2009-04-16 Anaphore, Inc. Trimeric il-1ra
US8999320B2 (en) * 2008-01-30 2015-04-07 The Rockefeller University Nanoscale bound bilayers, methods of use and production
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
WO2010057203A2 (en) * 2008-11-17 2010-05-20 The Board Of Regents Of The University Of Texas System Hdl particles for delivery of nucleic acids
US20120157380A1 (en) * 2009-06-05 2012-06-21 Nan Wang Pegylated human apoa-1 and process for production thereof
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
EP2511294B1 (en) * 2009-12-11 2014-02-26 Proyecto de Biomedicina Cima, S.L. Conjugates and compositions for immunotherapy and anti-tumoral treatment
JP2013531990A (ja) * 2010-06-15 2013-08-15 シー． ローヤー，マシュー アテローム性動脈硬化症治療のための組成物および方法
CN101923093B (zh) * 2010-07-13 2013-12-18 昆明理工大学 树鼩IgG的三抗体夹心ELISA检测方法
JP5860052B2 (ja) * 2010-08-30 2016-02-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ テトラネクチン−アポリポタンパク質ａ−ｉ、それを含有する脂質粒子及びその使用
ES2558751T3 (es) * 2010-08-30 2016-02-08 F. Hoffmann-La Roche Ag Alimento alcalino
JP2013544488A (ja) * 2010-08-30 2013-12-19 エフ．ホフマン−ラ ロシュ アーゲー テトラネクチン−アポリポタンパク質ａ−ｉ脂質粒子を産生するための方法、脂質粒子自体、及びその使用
WO2012028523A2 (en) * 2010-08-30 2012-03-08 F. Hoffmann-La Roche Ag Prokaryotic expression construct
US20120190609A1 (en) * 2010-08-30 2012-07-26 Martin Bader Method for producing a lipid particle, the lipid particle itself and its use
KR20130117760A (ko) * 2010-08-30 2013-10-28 에프. 호프만-라 로슈 아게 테트라넥틴-아포지단백질 a-i 입자의 제조 방법, 이에 의해 제조된 지질 입자 및 이의 용도
PT2673296T (pt) 2011-02-07 2019-01-31 Cerenis Therapeutics Holding Sa Complexos de lipoproteínas e sua fabricação e utilização
BR112013033562A2 (pt) 2011-08-25 2017-02-14 Hoffmann La Roche proteína de fusão de tetranectina-apolipoproteína a-i encurtada, uma partícula de lipídio que a contém e uso das mesmas
RU2014108241A (ru) * 2011-08-25 2015-09-27 Ф.Хоффманн-Ля Рош Аг Способ катион- и анионобменной хроматографии
KR20190084334A (ko) * 2011-12-21 2019-07-16 시에스엘 리미티드 아포지질단백질 제형을 위한 용량 용법
WO2013125769A1 (ko) * 2012-02-24 2013-08-29 성균관대학교 산학협력단 아포리포단백질을 포함하는 항체-약물 결합체
KR101536037B1 (ko) * 2012-02-24 2015-07-13 성균관대학교산학협력단 아포리포단백질을 포함하는 항체-약물 결합체
US9522945B2 (en) 2012-04-19 2016-12-20 Opko Biologics Ltd. Long-acting oxyntomodulin variants and methods of producing same
WO2014023315A1 (en) * 2012-08-10 2014-02-13 Aarhus Universitet Multimerization through beta-strand swapping in ccp domains
SG10202010383YA (en) 2012-11-20 2020-11-27 Opko Biologics Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
DK3004160T3 (da) * 2013-06-05 2023-01-23 Csl Ltd Fremgangsmåde til fremstilling af apolipoprotein a-i (apo a-i)
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
KR20170003611A (ko) 2014-05-02 2017-01-09 세레니스 쎄라퓨틱스 홀딩 에스에이 Ｈｄｌ 요법 마커
US10961286B2 (en) 2014-08-15 2021-03-30 Cornell University Nucleic acids, vectors, host cells, and methods for recombinantly producing water-soluble membrane proteins
EA201791275A1 (ru) 2014-12-10 2017-12-29 Опко Байолоджикс Лтд. Способы получения ctp-модифицированных полипептидов длительного действия
IL301728A (en) 2015-06-19 2023-05-01 Opko Biologics Ltd Long-term coagulation factors and methods for their preparation
DK3328881T3 (da) 2015-09-08 2019-10-07 Theripion Inc Apoa-1 fusionspolypeptider og relaterede sammensætninger og fremgangsmåder
HUE064463T2 (hu) 2016-07-11 2024-03-28 Opko Biologics Ltd Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások
WO2018136163A2 (en) * 2016-12-09 2018-07-26 Theripion, Inc. Tandem apoa-1 fusion polypeptides
WO2019030575A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding APOMÈRES
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Cargomers
JP2020534261A (ja) * 2017-09-08 2020-11-26 ザ ユニバーシティ オブ ブリストル 膜へのタンパク質送達
IL297336A (en) 2020-04-16 2022-12-01 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
KR20230079132A (ko) 2020-10-01 2023-06-05 아비오닉스 파마 에스에이 안질환을 치료하는 데 사용하기 위한 지질 결합 단백질-기반 복합체를 포함하는 조성물
AU2022258815A1 (en) 2021-04-15 2023-10-19 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
CN114940711B (zh) * 2021-10-25 2023-05-12 中山大学 载脂蛋白a-i模拟肽及其应用
KR20240167701A (ko) 2022-04-06 2024-11-27 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 안질환을 치료하는 방법
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
EP4536269A2 (en) 2022-06-10 2025-04-16 Abionyx Pharma SA Methods for treating acute conditions using lipid binding protein-based complexes
US20250352613A1 (en) 2022-06-10 2025-11-20 Stanislas FAGUER Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
CN115290776A (zh) * 2022-07-26 2022-11-04 云南大学 瘤牛锥虫病抗性蛋白的应用
KR20260010675A (ko) 2023-01-13 2026-01-21 아비오닉스 파마 에스에이 지질 결합 단백질 분자 치료
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025175130A1 (en) * 2024-02-16 2025-08-21 The Children's Medical Center Corporation Apom fusion constructs and methods of use in treating inflammatory diseases
CN119823289B (zh) * 2025-03-20 2025-06-10 内蒙古和讯生物科技有限公司 一种蛋白基生物材料及其制备方法与应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970144A (en) * 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US5068045A (en) * 1985-08-27 1991-11-26 Mobil Oil Corporation Grease composition containing alkoxylated amide borates
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
US5128318A (en) * 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
US5177189A (en) * 1989-08-18 1993-01-05 The Scripps Research Institute Polypeptide analogs of Apolipoprotein E
US5473039A (en) * 1989-08-18 1995-12-05 The Scripps Research Institute Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs
US5182364A (en) * 1990-02-26 1993-01-26 The Scripps Research Institute Polypeptide analogs of apolipoprotein E
WO1992009893A1 (en) * 1990-11-29 1992-06-11 Carbaugh John E DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS FOR LIPOPROTEIN(a)
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
WO1993000443A1 (en) * 1991-06-26 1993-01-07 Bio-Technology General Corp. Purification of recombinant apolipoprotein e from bacteria
US5408038A (en) * 1991-10-09 1995-04-18 The Scripps Research Institute Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
US5733549A (en) * 1992-08-14 1998-03-31 Shino-Test Corporation Peptides including amino acid sequences selected from lipoprotein (a) and apolipoprotein (a), antibodies recognizing these amino acid sequences, and methods of determination using these antibodies
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
SG52402A1 (en) 1992-12-22 1998-09-28 Univ Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins
KR100310739B1 (ko) 1993-02-04 2002-05-30 알란 스코브 단백질재생을위한개선된방법
SE9300937L (sv) 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Komposition för oral administrering av peptider
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
US5643757A (en) 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
GB9409768D0 (en) 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
AU718439B2 (en) * 1995-09-21 2000-04-13 Genentech Inc. Human growth hormone variants
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
EP1012280B1 (en) * 1997-06-11 2004-11-10 Borean Pharma A/S Trimerising module
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
AU757658B2 (en) 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis

Also Published As

Publication number Publication date
AU2002213843B2 (en) 2008-02-07
JP4344136B2 (ja) 2009-10-14
BR0115257A (pt) 2003-08-12
NO331274B1 (no) 2011-11-14
US6897039B2 (en) 2005-05-24
CA2428114A1 (en) 2002-05-16
AU1384302A (en) 2002-05-21
EP2343317A1 (en) 2011-07-13
US20050142639A1 (en) 2005-06-30
AU2002213843A2 (en) 2002-05-21
EP1335938B1 (en) 2010-09-22
CN1486327A (zh) 2004-03-31
CA2428114C (en) 2013-07-23
US20020156007A1 (en) 2002-10-24
US20050096277A1 (en) 2005-05-05
NO20032101L (no) 2003-07-08
WO2002038609A2 (en) 2002-05-16
CN1268641C (zh) 2006-08-09
JP2009118849A (ja) 2009-06-04
EP1335938A2 (en) 2003-08-20
US20090136467A1 (en) 2009-05-28
JP2004522424A (ja) 2004-07-29
WO2002038609A3 (en) 2002-09-26
CY1111118T1 (el) 2015-06-11

Similar Documents

Publication Publication Date Title
DK1307486T3 (da) Somatostatinanaloger
DE60133511D1 (de) Fluorierte Ionomere
EP1353683A4 (en) ANALOGS BY GHRELIN
NO331274B1 (no) Apolipoproteinanaloger
ATE330937T1 (de) Glyburid-zusammensetzung
DE50114386D1 (de) Ng
FI20002644L (fi) Liitäntäalusta
DE60107598D1 (de) Smart-skin strukturen
DK1235777T3 (da) Vitamin D-analoger
DE60137169D1 (de) Entwicklungsgerät
NO20023246D0 (no) Hårstylingsfremgangsmåte
DK1235824T3 (da) D-vitaminanaloge forbindelser
ATE266316T1 (de) Fungizide zusammensetzungen
AR027931A1 (es) Antitranspirantes
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
DE60104126D1 (de) Fungizide formulierung
ATE268116T1 (de) Mesotrion-formulierungen
AR027982A1 (es) Aril- y heteroarilsulfonatos
FI20002120A0 (fi) Sammutin
FR2817889B1 (fr) Coffrage
ATA12252000A (de) Regensinkkasten
ATA17542000A (de) Hydraulikzylinder
ATA19392000A (de) Kippflügelflugzeug
ATA21172000A (de) Hackbrett
SE0004047D0 (sv) CC-Kottling

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees